CNTLN抗体;CNTLN Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13065(CNTLN Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of CNTLN Antibodies**

CNTLN (Contactin) antibodies target proteins belonging to the Contactin family, a subgroup of immunoglobulin (Ig) cell adhesion molecules (CAMs) critical for nervous system development and function. Contactins, including CNTN1-CNTN6. are membrane-bound glycoproteins that mediate cell-cell interactions, axon guidance, and synapse formation by binding to extracellular partners like Contactin-associated proteins (Caspr) or receptor tyrosine phosphatases. These proteins are predominantly expressed in neurons and glial cells, playing roles in myelination, neuronal circuit assembly, and plasticity.

CNTLN antibodies are essential tools in neuroscience research, enabling the detection and localization of Contactin proteins in tissues or cultured cells. Dysregulation of Contactins has been linked to neurological disorders such as autism spectrum disorders, schizophrenia, and neurodegenerative diseases. For example, mutations in *CNTNAP2* (encoding Caspr2) are associated with epilepsy and intellectual disability. Antibodies against specific Contactin isoforms help elucidate their roles in disease mechanisms, validate protein expression in models, and explore therapeutic targets.

Commercial CNTLN antibodies are typically developed in hosts like rabbits or mice, validated for applications such as Western blot, immunohistochemistry, and immunofluorescence. Challenges include ensuring isoform specificity due to structural similarities among Contactin family members. Ongoing research continues to refine antibody specificity and explore their diagnostic or therapeutic potential in neurological conditions.